



HI 2016 Financial Results

as of June 30, 2016



SAFE HARBOR STATEMENT

Forward-looking statements involve risks.

This company presentation contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this.

This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected.

It is not planned to update these forward-looking statements.





- I. Highlights of the first six months of 2016
- 2. Financials
- 3. Acquisitions
- 4. Outlook & Focus



Financials

Acquisitions

Outlook & Focus

Highlights 6M/2016

• Two major company acquisitions successfully executed

Consolidated as of April 1, 2016

diatron • •

Budapest, Hungary

~ € 34 million sales in 2015

~ 230 employees

Consolidated as of July 1, 2016



Former Sony DADC BioSciences

Anif near Salzburg, Austria

~ € 14 million sales 2015/16

~ I30 employees



Financials

Acquisitions

Outlook & Focus

Highlights 6M/2016

- Revenues increased by 11.5% to € 78.0 million
- Rising EBIT margin in Q2
- Dividend pay out after AGM in June 2016 of € 0.75 per share (2015: € 0.70)
- Number of employees: 606 +7.8% organic June 30, 2016 (6M/2015: 562)

842 including Diatron

~ 960 Total as of July, 2016 (incl. Stratec Consumables)

Several new programs in pipeline



Financials

Acquisitions

Outlook & Focus

- 1. Highlights of the first six months of 2016
- 2. Financials
- 3. Acquisitions
- 4. Outlook & Focus



Financials

Acquisitions

Outlook & Focus

FINANCIALS AT A GLANCE

Key figures after the first six months

(€ million)	June 30, 2016	June 30, 2015	Change
Sales	78.0	70.0	+ 11.5%
EBIT	12.61	12.0	+ 5.3%
EBIT margin (%)	16.2 ¹	17.1	- 95 bps
Cons. net income	10.32	9.8	+ 5.1%
Earnings per share (€)	0.872	0.83	+ 4.6%

¹ 2016 figure adjusted to exclude non-recurring items for transaction activities

² 2016 figure additionally adjusted to exclude financing expenses and tax expenses in connection with the acquisition of the Diatron Group and non-recurring items arising from the external tax audit for the assessment periods from 2009 to 2013.



Financials

Acquisitions

Outlook & Focus

Adjustments as of June 30, 2016

in € thousand Adjusted consolidated net income	01.0106.30.2016	
Adjustments		
Expenses due to company acquisitions	-985	
Internal integration expenses	-218	
Realization of hidden reserves identified	-263	
Expenses due to purchase price allocation	-1,199	
Financing expenses due to company acquisitions and external tax audit	-397	
Current tax expenses	-1,052	
Deferred tax expenses	201	
Consolidated net income	6,399	
Earnings per share (€)	0.54	

in € thousand	01.01 06.30.2016	
Adjusted EBIT	12,616	
Adjustments		
Expenses due to company acquisitions	-985	
Internal integration expenses	-218	
Expenses due to purchase price allocation	-1,199	
Realization of hidden reserves identified	-263	
EBIT	9,951	




Financials

Acquisitions

Outlook & Focus

SALES

6-Months Sales compared to Annual Sales



6M/2016 Sales

- +11.5% to € 78.0 Mio.
- Diatron: €10.5 Mio. in Q2

Q2/2016 Sales organically

+2.6% to € 36.3 Mio.
(Q2/2015: € 35.5 Mio.)




Financials

Acquisitions

Outlook & Focus

EBIT & EBIT MARGIN

As of June 30



EBIT margin picking up:

- Reinstating economies of scale in Q2
- Q2/2016 (organic): 17.49% +16 bps (Q2/2015:17.33%)
- 6M/2016: 16.17% / 95 bps (6m/2015: 17.12%)

¹ figures exclude non-recurring special effects




Financials

Acquisitions

Outlook & Focus

EARNINGS AFTER SIX MONTHS

Earnings per share as of June 30



- Adjusted EPS at € 0.87 (6M/2015: € 0.83)
- Adjusted 6M tax rate at 15.9% (6M/2015: 19.2%)
- Dividend pay out per share at €
 0.75
 (previous year: € 0.70)

¹ figures exclude non-recurring special effects



Financials

Acquisitions

Outlook & Focus

- 1. Highlights of the first six months of 2016
- 2. Financials
- 3. Acquisitions
- 4. Outlook & Focus




Financials

Acquisitions

Outlook & Focus

DIATRON – EXPANDING THE VALUE CHAIN





Financials

Acquisitions

Outlook & Focus

DIATRON PRODUCTS

Hematology analyzers



Consumables





Clinical chemistry analyzers



Spare parts and others



- For use in small and medium-sized labs
- Throughput
 50 tests per hour

 Hematology and clinical chemistry reagents

- For use in small, medium and large laboratories
- Benchtop and free-standing devices

- Spare parts for hematology and clinical chemistry analyzers
- High availability of spare parts



..000

Financials

Acquisitions

Outlook & Focus

EXPANDING THE LAB AUTOMATION VALUE CHAIN



Analyzer System

Software

Consumables

Smart Consumables

sample prep chemistry

Reagents

Market access



















- Development - Production
- Development - Production
- Development +
- Development
- Production
- Development
- Production

stratecoo

Diagnostic Companies



Financials

Acquisitions

Outlook & Focus

PRODUCT EXAMPLES STRATEC Consumables

Single molecule array



Polymer chip



Polymer chip



State-of-the-art array containing over 200,000 femtoliter-sized wells and integrated microfluidics.

Disposable polymer chip to target and amplify hundreds to thousands of specific regions of the genome using RainDance's microdroplet-based PCR for subsequent sequencing Polymer chip for gelelectrophoresis DNA analysis and DNA fragment isolation consisting of a fluidic chip, electrodes and gaskets for interfacing with the instrument and caddy.



Financials

Acquisitions

Outlook & Focus

1. Highlights of the first six months of 2016

www.stratec.com

- 2. Financials
- 3. Acquisitions
- 4. Outlook & Focus



Financials

Acquisitions

Outlook & Focus

STRATEC - FINANCIAL GUIDANCE

	FY 2016	FY 2017
Revenues	175 – 182 € million	205 – 220 € million
EBIT-Margin	16.0 % - 17.5 %	Slight growth compared to 2016

Organic growth (excluding Diatron and STRATEC Consumables acquisitions): CAGR ~6 % for 2016 and 2017



Financials

Acquisitions

Outlook & Focus

Focus in 2016 and beyond

- Post merger integration process
- Expanding role as developer and manufacturer of instruments, consumables and software
- Significant synergies through joint development & production
- Reduction of integration risk withing projects for partners
- Achieve milestones & market launches





stratec • biomedical

TICKER

Symbol: SBS.DE

Bloomberg: SBS:GR

Reuters: SBSG.DE

ISIN: DE0007289001

WKN: 728900



